Bausch Health Companies (BHC) Financials

$4.53 -0.08 (-1.74%)

Closing price 05/30/2025 03:59 PM Eastern

Extended Trading

$4.51 -0.02 (-0.33%)

As of 05/30/2025 06:52 PM Eastern

Annual Income Statements for Bausch Health Companies

This table shows Bausch Health Companies' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015	12/31/2014
Net Income / (Loss) Attributable to Common Shareholders	-46	-592	-225	-948	-6,316	-1,788	-4,148	2,404	-2,409	-292	881
Consolidated Net Income / (Loss)	-72	-611	-212	-937	-559	-1,783	-4,144	2,404	-2,408	-288	880
Net Income / (Loss) Continuing Operations	-72	-611	-212	-937	-6,315	-1,783	-4,144	2,404	-2,408	-288	880
Total Pre-Tax Income	167	-390	-129	-1,024	-6,690	-1,837	-4,154	-1,741	-2,435	-155	1,054
Total Operating Income	1,546	963	454	450	676	-203	-2,384	102	-566	1,527	2,001
Total Gross Profit	6,843	6,198	5,760	6,040	0.00	6,251	6,029	6,176	7,063	7,915	6,028
Total Revenue	9,625	8,757	8,124	8,434	0.00	8,601	8,380	8,724	9,674	10,447	8,206
Operating Revenue	9,625	8,757	8,124	8,434	-	8,601	8,380	8,724	9,674	10,447	8,206
Total Cost of Revenue	2,782	2,559	2,364	2,394	0.00	2,350	2,351	2,548	2,611	2,532	2,178
Operating Cost of Revenue	2,782	2,559	2,364	2,394	0.00	2,350	2,351	2,548	2,611	2,532	2,178
Total Operating Expenses	5,297	5,235	5,306	5,590	5,080	6,454	8,413	6,074	7,629	6,388	4,027
Selling, General & Admin Expense	3,296	2,917	2,625	2,624	2,367	2,554	2,473	2,582	2,810	2,700	2,026
Research & Development Expense	616	604	529	465	452	471	413	361	455	440	266
Amortization Expense	1,077	1,077	1,215	1,375	1,645	1,897	2,644	2,690	2,673	2,257	1,427
Other Operating Expenses / (Income)	247	28	35	373	502	1,426	-29	-637	60	325	-219
Impairment Charge	29	547	839	703	114	75	2,890	1,026	1,499	304	145
Restructuring Charge	32	62	63	50	-	31	22	52	132	362	382
Total Other Income / (Expense), net	-1,379	-1,353	-583	-1,474	-1,610	-1,634	-1,770	-1,843	-1,869	-1,682	-947
Interest Expense	1,365	1,327	589	1,488	1,593	1,654	1,804	1,962	1,836	1,583	1,101
Interest & Investment Income	33	26	14	7.00	13	12	11	12	8.00	4.00	298
Other Income / (Expense), net	-47	-52	-8.00	7.00	-30	8.00	23	107	-41	-103	-144
Income Tax Expense	239	221	83	-87	-375	-54	-10	-4,145	-27	133	174
Net Income / (Loss) Attributable to Noncontrolling Interest	-26	-19	13	11	1.00	5.00	4.00	0.00	1.00	4.00	-1.00
Basic Earnings per Share	($0.13)	($1.62)	($0.62)	($2.64)	($1.58)	($5.08)	($11.81)	$6.86	($6.94)	($0.85)	$2.63
Weighted Average Basic Shares Outstanding	368M	364.90M	362M	358.90M	355M	352.10M	351.30M	350.20M	347.30M	342.70M	335.40M
Diluted Earnings per Share	($0.13)	($1.62)	($0.62)	($2.64)	($1.58)	($5.08)	($11.81)	$6.83	($6.94)	($0.85)	$2.58
Weighted Average Diluted Shares Outstanding	368M	364.90M	362M	358.90M	355M	352.10M	351.30M	351.80M	347.30M	342.70M	341.50M
Weighted Average Basic & Diluted Shares Outstanding	367.93M	365.41M	362.04M	359.65M	355M	352.10M	351.30M	350.40M	347.10M	343.50M	323.80M

This table shows Bausch Health Companies' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Income / (Loss) Attributable to Common Shareholders	-58	93	-85	10	-64	-39	-378	26	-201	-410	399
Consolidated Net Income / (Loss)	-86	98	-92	-1.00	-77	-47	-382	27	-209	-410	403
Net Income / (Loss) Continuing Operations	-86	98	-92	-1.00	-77	-47	-382	27	-209	-410	403
Total Pre-Tax Income	-47	209	-21	48	-69	-7.00	-326	79	-136	-357	439
Total Operating Income	276	558	318	389	281	362	14	412	175	-236	244
Total Gross Profit	1,558	1,832	1,814	1,684	1,513	1,703	1,615	1,518	1,362	1,541	1,462
Total Revenue	2,259	2,559	2,510	2,403	2,153	2,408	2,238	2,167	1,944	2,193	2,046
Operating Revenue	2,259	2,559	2,510	2,403	2,153	2,408	2,238	2,167	1,944	2,193	2,046
Total Cost of Revenue	701	727	696	719	640	705	623	649	582	652	584
Operating Cost of Revenue	701	727	696	719	640	705	623	649	582	652	584
Total Operating Expenses	1,282	1,274	1,496	1,295	1,232	1,341	1,601	1,106	1,187	1,777	1,218
Selling, General & Admin Expense	867	820	850	832	794	766	715	711	725	666	661
Research & Development Expense	143	163	146	156	151	152	153	156	143	142	133
Amortization Expense	256	259	274	270	274	282	253	269	273	313	290
Other Operating Expenses / (Income)	15	2.00	225	20	0.00	28	60	-83	23	29	4.00
Impairment Charge	0.00	23	0.00	5.00	1.00	91	406	37	13	622	120
Restructuring Charge	1.00	7.00	1.00	12	12	22	14	16	10	5.00	10
Total Other Income / (Expense), net	-323	-349	-339	-341	-350	-369	-340	-333	-311	-121	195
Interest Expense	330	337	346	338	344	362	339	319	307	115	-185
Interest & Investment Income	11	9.00	7.00	8.00	9.00	7.00	6.00	7.00	6.00	6.00	3.00
Other Income / (Expense), net	-4.00	-21	0.00	-11	-15	-14	-7.00	-21	-10	-12	7.00
Income Tax Expense	39	111	71	49	8.00	40	56	52	73	53	36
Net Income / (Loss) Attributable to Noncontrolling Interest	-28	5.00	-7.00	-11	-13	-8.00	-4.00	1.00	-8.00	-	4.00
Basic Earnings per Share	($0.16)	$0.24	($0.23)	$0.03	($0.17)	($0.11)	($1.03)	$0.07	($0.55)	($1.13)	$1.10
Weighted Average Basic Shares Outstanding	369.60M	368M	368.40M	367.90M	366.80M	364.90M	365.40M	364.80M	363.30M	362M	362.50M
Diluted Earnings per Share	($0.16)	$0.24	($0.23)	$0.03	($0.17)	($0.11)	($1.03)	$0.07	($0.55)	($1.13)	$1.10
Weighted Average Diluted Shares Outstanding	369.60M	368M	368.40M	370.20M	366.80M	364.90M	365.40M	367.10M	363.30M	362M	363.40M
Weighted Average Basic & Diluted Shares Outstanding	369.55M	367.93M	367.80M	367.10M	366.80M	365.41M	365.20M	364.33M	363.72M	362.04M	361.87M

This table details how cash moves in and out of Bausch Health Companies' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015	12/31/2014
Net Change in Cash & Equivalents	239	371	-1,528	303	-1,428	2,521	-48	255	-55	274	-277
Net Cash From Operating Activities	1,597	1,032	-728	1,426	1,111	1,501	1,501	2,290	2,087	2,257	2,312
Net Cash From Continuing Operating Activities	1,597	1,032	-728	1,426	1,111	1,501	1,501	2,290	2,087	2,257	2,312
Net Income / (Loss) Continuing Operations	-72	-611	-212	-937	-559	-1,783	-4,144	2,404	-2,408	-288	880
Consolidated Net Income / (Loss)	-72	-611	-212	-937	-559	-1,783	-4,144	2,404	-2,408	-288	880
Depreciation Expense	1,267	1,264	1,394	1,552	1,825	2,075	2,819	2,858	2,866	2,467	1,614
Amortization Expense	137	88	99	55	61	63	79	151	118	145	70
Non-Cash Adjustments To Reconcile Net Income	192	822	-1,437	1,109	625	1,694	2,873	419	1,857	761	312
Changes in Operating Assets and Liabilities, net	73	-531	-572	-353	-841	-548	-126	-3,542	-346	-828	-564
Net Cash From Investing Activities	-454	-2,145	-303	409	-261	-419	-196	2,887	-125	-15,577	-100
Net Cash From Continuing Investing Activities	-454	-2,145	-303	409	-261	-419	-196	2,887	-125	-15,577	-100
Purchase of Property, Plant & Equipment	-337	-215	-218	-269	-302	-270	-157	-171	-235	-235	-292
Acquisitions	-3.00	-57	-50	-14	-7.00	-188	-78	-165	-86	-15,526	-1,357
Purchase of Investments	-148	-1,917	-62	-19	-4.00	-16	-7.00	-7.00	-1.00	-49	-72
Divestitures	7.00	5.00	5.00	669	21	45	39	3,253	199	0.00	76
Sale and/or Maturity of Investments	14	26	22	15	8.00	10	7.00	2.00	17	251	53
Other Investing Activities, net	13	13	0.00	27	23	0.00	0.00	-25	-19	-31	0.00
Net Cash From Financing Activities	-868	1,475	-474	-1,513	-2,294	1,443	-1,353	-4,963	-1,963	13,624	-2,460
Net Cash From Continuing Financing Activities	-868	1,475	-474	-1,513	-2,294	1,443	-1,353	-4,963	-1,963	13,624	-2,460
Repayment of Debt	-1,476	-1,757	-7,928	-3,478	-5,684	-4,454	-10,232	-14,339	-2,545	-5,289	-3,968
Issuance of Debt	661	3,291	6,836	2,100	3,455	5,972	8,944	9,425	1,223	17,825	1,649
Other Financing Activities, net	-53	-59	618	-135	-65	-75	-65	-49	-641	-264	-133
Effect of Exchange Rate Changes	-36	9.00	-23	-19	16	-4.00	-	41	-54	-30	-29

This table details how cash moves in and out of Bausch Health Companies' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Change in Cash & Equivalents	-44	451	127	-132	-207	182	192	57	-60	94	-1,382
Net Cash From Operating Activities	211	601	405	380	211	390	282	206	154	475	-1,263
Net Cash From Continuing Operating Activities	211	601	405	380	211	390	282	206	154	475	-1,263
Net Income / (Loss) Continuing Operations	-86	98	-92	-1.00	-77	-47	-382	27	-209	-410	403
Consolidated Net Income / (Loss)	-86	98	-92	-1.00	-77	-47	-382	27	-209	-410	403
Depreciation Expense	305	307	322	318	320	329	301	315	319	360	335
Amortization Expense	37	35	34	34	34	37	28	12	11	13	22
Non-Cash Adjustments To Reconcile Net Income	29	107	18	41	26	157	486	85	94	515	-1,658
Changes in Operating Assets and Liabilities, net	-74	54	123	-12	-92	-86	-151	-233	-61	-3.00	-365
Net Cash From Investing Activities	-130	-200	-102	-79	-73	-148	-1,889	-30	-78	-136	-53
Net Cash From Continuing Investing Activities	-130	-200	-102	-79	-73	-148	-1,889	-30	-78	-136	-53
Purchase of Property, Plant & Equipment	-115	-106	-71	-78	-82	-98	-42	-28	-47	-66	-54
Acquisitions	-9.00	-1.00	-	-1.00	-1.00	-46	-4.00	-3.00	-4.00	-30	-5.00
Purchase of Investments	-16	-96	-47	-2.00	-3.00	-17	-1,858	2.00	-44	-47	-1.00
Divestitures	0.00	-	5.00	1.00	1.00	-	4.00	1.00	0.00	5.00	-
Sale and/or Maturity of Investments	4.00	3.00	4.00	1.00	6.00	13	4.00	-2.00	11	2.00	7.00
Other Investing Activities, net	6.00	-	7.00	-	6.00	-	7.00	-	6.00	-	-
Net Cash From Financing Activities	-146	85	-189	-424	-340	-79	1,816	-120	-142	-276	-36
Net Cash From Continuing Financing Activities	-146	85	-189	-424	-340	-79	1,816	-120	-142	-276	-36
Repayment of Debt	-173	-411	-176	-495	-394	-206	-860	-413	-278	-623	-190
Issuance of Debt	50	506	-	80	75	146	2,690	300	155	355	161
Other Financing Activities, net	-23	-10	-13	-9.00	-21	-19	-14	-7.00	-19	-8.00	-7.00
Effect of Exchange Rate Changes	21	-35	13	-9.00	-5.00	19	-17	1.00	6.00	31	-30

This table presents Bausch Health Companies' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015	12/31/2014
Total Assets	26,523	27,350	25,686	29,202	31,199	33,863	32,492	37,497	43,529	48,965	26,305
Total Current Assets	5,774	5,596	4,247	5,607	5,342	6,969	4,211	4,746	5,077	5,507	4,132
Cash & Equivalents	1,181	947	564	582	605	3,243	721	720	542	597	323
Restricted Cash	20	15	-	1,537	1,211	1.00	2.00	77	0.00	-	-
Accounts Receivable	2,140	1,998	1,790	1,775	1,577	1,839	1,865	2,130	2,517	2,687	2,076
Inventories, net	1,595	1,544	1,090	993	1,094	1,107	934	1,048	1,061	1,257	889
Prepaid Expenses	838	1,092	776	720	855	779	689	771	696	963	651
Plant, Property, & Equipment, net	1,780	1,707	1,600	1,598	1,567	1,466	1,353	1,403	1,312	1,442	1,312
Total Noncurrent Assets	18,969	20,047	19,839	21,997	24,290	25,428	26,928	31,348	37,140	42,016	20,861
Goodwill	11,087	11,183	11,547	12,457	13,044	13,126	13,142	15,593	15,794	18,553	9,361
Intangible Assets	5,551	6,456	5,800	6,948	8,445	10,201	12,001	15,211	18,884	23,083	11,278
Noncurrent Deferred & Refundable Income Taxes	1,968	2,101	2,166	2,252	2,137	1,690	1,676	433	146	156	54
Other Noncurrent Operating Assets	363	307	326	340	664	411	109	111	184	224	167
Total Liabilities & Shareholders' Equity	26,523	27,350	25,686	29,202	31,199	33,863	32,492	37,497	43,529	48,965	26,305
Total Liabilities	26,845	27,432	25,426	29,236	30,594	32,727	29,677	31,553	40,271	42,936	20,903
Total Current Liabilities	6,752	4,302	3,941	5,198	4,913	6,248	3,836	4,268	3,609	5,313	2,708
Short-Term Debt	2,674	450	432	0.00	-	1,234	228	209	1.00	1,020	143
Accounts Payable	656	719	521	407	337	503	411	365	324	434	398
Accrued Expenses	3,422	3,133	2,988	4,791	4,576	4,511	3,197	3,694	3,227	3,859	2,157
Total Noncurrent Liabilities	20,093	23,130	21,485	24,038	25,681	26,479	25,841	27,285	36,662	37,623	18,195
Long-Term Debt	18,942	21,938	20,334	22,654	23,925	24,661	24,077	25,235	29,845	30,265	15,228
Noncurrent Deferred & Payable Income Tax Liabilities	128	163	202	529	528	705	885	1,180	5,434	6,023	2,324
Other Noncurrent Operating Liabilities	1,023	1,029	949	855	1,228	1,113	879	870	1,326	1,144	403
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	-322	-82	260	-34	605	1,136	2,815	5,944	3,258	6,029	5,402
Total Preferred & Common Equity	-1,279	-1,022	-692	-106	535	1,063	2,733	5,849	3,152	5,910	5,279
Total Common Equity	-1,279	-1,022	-692	-106	535	1,063	2,733	5,849	3,152	5,910	5,279
Common Stock	10,724	10,637	10,550	10,779	10,681	10,601	10,534	10,470	10,389	10,202	8,593
Retained Earnings	-9,824	-9,778	-9,186	-8,961	-8,013	-7,452	-5,664	-2,725	-5,129	-2,750	-2,398
Accumulated Other Comprehensive Income / (Loss)	-2,179	-1,881	-2,056	-1,924	-2,133	-2,086	-2,137	-1,896	-2,108	-1,542	-916
Noncontrolling Interest	957	940	952	72	70	73	82	95	106	119	122

This table presents Bausch Health Companies' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q3 2024	Q2 2024	Q1 2024	Q3 2023	Q2 2023	Q1 2023	Q3 2022
Period end date	3/31/2025	9/30/2024	6/30/2024	3/31/2024	9/30/2023	6/30/2023	3/31/2023	9/30/2022
Total Assets	26,421	26,540	26,495	26,913	27,064	25,503	25,445	26,298
Total Current Assets	5,732	5,351	5,211	5,396	5,048	4,461	4,237	4,010
Cash & Equivalents	1,134	719	595	733	760	579	518	486
Restricted Cash	23	31	28	22	20	9.00	13	11
Accounts Receivable	2,072	2,094	2,102	2,048	1,948	1,743	1,688	1,739
Inventories, net	1,613	1,655	1,612	1,636	1,272	1,240	1,222	1,056
Prepaid Expenses	890	852	874	957	1,048	890	796	718
Plant, Property, & Equipment, net	1,882	1,789	1,738	1,713	1,584	1,599	1,596	1,507
Total Noncurrent Assets	18,807	19,400	19,546	19,804	20,432	19,443	19,612	20,781
Goodwill	11,153	11,171	11,127	11,160	11,187	11,628	11,579	12,044
Intangible Assets	5,297	5,652	5,903	6,183	6,728	5,299	5,552	6,024
Noncurrent Deferred & Refundable Income Taxes	1,977	2,188	2,187	2,149	2,189	2,191	2,163	2,372
Other Noncurrent Operating Assets	380	389	329	312	328	325	318	341
Total Liabilities & Shareholders' Equity	26,421	26,540	26,495	26,913	27,064	25,503	25,445	26,298
Total Liabilities	26,661	26,782	26,722	27,087	27,299	25,232	25,300	25,865
Total Current Liabilities	4,256	4,506	4,369	4,405	4,224	3,967	3,923	3,831
Short-Term Debt	282	453	452	538	536	444	446	411
Accounts Payable	620	667	579	642	569	515	561	486
Accrued Expenses	3,354	3,386	3,338	3,225	3,119	3,008	2,916	2,934
Total Noncurrent Liabilities	22,405	22,028	22,353	22,682	23,075	21,265	21,377	22,034
Long-Term Debt	21,228	21,054	21,208	21,536	21,894	20,108	20,207	20,804
Noncurrent Deferred & Payable Income Tax Liabilities	134	169	170	170	213	215	205	422
Other Noncurrent Operating Liabilities	1,043	805	975	976	968	942	965	808
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	-240	-242	-227	-174	-235	271	145	433
Total Preferred & Common Equity	-1,183	-1,174	-1,175	-1,115	-1,180	-663	-800	-525
Total Common Equity	-1,183	-1,174	-1,175	-1,115	-1,180	-663	-800	-525
Common Stock	10,728	10,690	10,664	10,644	10,610	10,600	10,576	10,516
Retained Earnings	-9,882	-9,917	-9,832	-9,842	-9,739	-9,361	-9,387	-8,776
Accumulated Other Comprehensive Income / (Loss)	-2,029	-1,947	-2,007	-1,917	-2,051	-1,902	-1,989	-2,265
Noncontrolling Interest	943	932	948	941	945	934	945	958

This table displays calculated financial ratios and metrics derived from Bausch Health Companies' official financial filings.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015	12/31/2014
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	9.91%	7.79%	-3.68%	0.00%	-100.00%	2.64%	-3.94%	-9.82%	-7.40%	27.31%	42.23%
EBITDA Growth	28.28%	16.71%	-6.06%	-18.48%	30.31%	261.83%	-83.31%	35.38%	-41.11%	13.98%	109.97%
EBIT Growth	64.54%	104.26%	-2.41%	-29.26%	431.28%	91.74%	-1,229.67%	134.43%	-142.63%	-23.32%	543.30%
NOPAT Growth	-198.88%	112.11%	0.89%	-33.43%	433.00%	91.48%	-2,437.25%	118.02%	-137.07%	-36.02%	682.82%
Net Income Growth	88.22%	-188.21%	77.37%	-67.62%	68.65%	56.97%	-272.38%	199.83%	-736.11%	-132.73%	201.90%
EPS Growth	91.98%	-161.29%	76.52%	-67.09%	68.90%	56.99%	-272.91%	198.42%	-716.47%	-132.95%	195.56%
Operating Cash Flow Growth	54.75%	241.76%	-151.05%	28.35%	-25.98%	0.00%	-34.45%	9.73%	-7.53%	-2.38%	121.88%
Free Cash Flow Firm Growth	381.13%	-158.27%	-85.89%	63.50%	-37.35%	-2.27%	1,167.29%	-103.92%	139.71%	-557.67%	138.80%
Invested Capital Growth	-5.86%	4.31%	-0.19%	-9.74%	-4.51%	-9.89%	-13.71%	1.02%	-17.52%	79.53%	-7.46%
Revenue Q/Q Growth	1.59%	2.52%	2,746.25%	1,889.15%	-100.00%	1.21%	-0.50%	-2.68%	-3.54%	5.40%	1.97%
EBITDA Q/Q Growth	6.03%	35.19%	-24.05%	17.27%	66.25%	-37.52%	4.88%	-7.82%	-1.74%	-0.47%	7.76%
EBIT Q/Q Growth	14.43%	189.21%	-57.81%	437.65%	252.00%	-121.31%	12.33%	-66.07%	-10.61%	-20.23%	19.79%
NOPAT Q/Q Growth	-170.53%	163.84%	-57.05%	476.92%	271.14%	-122.61%	12.71%	-82.23%	-3.04%	-39.86%	-12.96%
Net Income Q/Q Growth	66.82%	37.27%	-178.52%	19.29%	70.95%	-193.26%	-25.96%	74.20%	-5.49%	-147.96%	74.92%
EPS Q/Q Growth	72.92%	38.64%	-186.11%	19.51%	71.01%	-191.95%	-25.77%	76.03%	-5.63%	-148.85%	85.61%
Operating Cash Flow Q/Q Growth	15.22%	-7.61%	38.25%	-20.60%	16.82%	-5.36%	-14.72%	2.97%	-3.92%	-9.46%	31.45%
Free Cash Flow Firm Q/Q Growth	-63.40%	-2,345.88%	487.41%	-7.93%	-23.17%	6.16%	69.33%	-105.82%	306.88%	-12.89%	9.01%
Invested Capital Q/Q Growth	-3.23%	-0.33%	-3.26%	0.90%	-1.29%	-5.98%	-2.22%	0.63%	-11.09%	2.19%	-1.16%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	71.10%	70.78%	70.90%	71.61%	0.00%	72.68%	71.95%	70.79%	73.01%	75.76%	73.46%
EBITDA Margin	30.16%	25.84%	23.87%	24.47%	0.00%	22.59%	6.41%	36.89%	24.57%	38.63%	43.15%
Operating Margin	16.06%	11.00%	5.59%	5.34%	0.00%	-2.36%	-28.45%	1.17%	-5.85%	14.62%	24.38%
EBIT Margin	15.57%	10.40%	5.49%	5.42%	0.00%	-2.27%	-28.17%	2.40%	-6.27%	13.63%	22.63%
Profit (Net Income) Margin	-0.75%	-6.98%	-2.61%	-11.11%	0.00%	-20.73%	-49.45%	27.56%	-24.89%	-2.76%	10.72%
Tax Burden Percent	-43.11%	156.67%	164.34%	91.50%	8.36%	97.06%	99.76%	-138.08%	98.89%	185.81%	83.49%
Interest Burden Percent	11.14%	-42.81%	-28.92%	-224.07%	-1,035.60%	942.05%	175.94%	-833.01%	401.15%	-10.88%	56.76%
Effective Tax Rate	143.11%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	16.51%
Return on Invested Capital (ROIC)	-3.22%	3.22%	1.55%	1.46%	0.00%	-0.57%	-5.86%	0.23%	-1.18%	3.74%	7.85%
ROIC Less NNEP Spread (ROIC-NNEP)	-0.38%	-2.95%	-1.05%	-4.41%	0.00%	-7.66%	-16.12%	9.26%	-8.15%	-2.19%	2.90%
Return on Net Nonoperating Assets (RNNOA)	38.86%	-689.74%	-189.16%	-329.65%	0.00%	-89.69%	-88.77%	52.01%	-50.67%	-8.78%	8.70%
Return on Equity (ROE)	35.64%	-686.52%	-187.61%	-328.20%	-64.22%	-90.26%	-94.62%	52.25%	-51.86%	-5.04%	16.55%
Cash Return on Invested Capital (CROIC)	2.82%	-0.99%	1.74%	11.70%	6.65%	9.84%	8.86%	-0.78%	18.02%	-53.16%	15.61%
Operating Return on Assets (OROA)	5.56%	3.44%	1.63%	1.51%	0.00%	-0.59%	-6.75%	0.52%	-1.31%	3.78%	6.84%
Return on Assets (ROA)	-0.27%	-2.30%	-0.77%	-3.10%	0.00%	-5.37%	-11.84%	5.93%	-5.21%	-0.77%	3.24%
Return on Common Equity (ROCE)	203.01%	6,610.62%	662.45%	-246.58%	-58.94%	-86.71%	-92.71%	51.11%	-50.60%	-4.93%	16.18%
Return on Equity Simple (ROE_SIMPLE)	5.63%	59.78%	30.64%	883.96%	-104.49%	-167.73%	-151.63%	41.10%	-76.40%	-4.87%	16.67%
Net Operating Profit after Tax (NOPAT)	-667	674	318	315	473	-142	-1,669	71	-396	1,069	1,671
NOPAT Margin	-6.93%	7.70%	3.91%	3.73%	0.00%	-1.65%	-19.91%	0.82%	-4.10%	10.23%	20.36%
Net Nonoperating Expense Percent (NNEP)	-2.84%	6.17%	2.60%	5.87%	4.61%	7.10%	10.26%	-9.03%	6.97%	5.93%	4.96%
Return On Investment Capital (ROIC_SIMPLE)	-3.13%	3.02%	1.51%	-	-	-	-	-	-	-	-
Cost of Revenue to Revenue	28.90%	29.22%	29.10%	28.39%	0.00%	27.32%	28.05%	29.21%	26.99%	24.24%	26.54%
SG&A Expenses to Revenue	34.24%	33.31%	32.31%	31.11%	0.00%	29.69%	29.51%	29.60%	29.05%	25.84%	24.69%
R&D to Revenue	6.40%	6.90%	6.51%	5.51%	0.00%	5.48%	4.93%	4.14%	4.70%	4.21%	3.24%
Operating Expenses to Revenue	55.03%	59.78%	65.31%	66.28%	0.00%	75.04%	100.39%	69.62%	78.86%	61.15%	49.07%
Earnings before Interest and Taxes (EBIT)	1,499	911	446	457	646	-195	-2,361	209	-607	1,424	1,857
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	2,903	2,263	1,939	2,064	2,532	1,943	537	3,218	2,377	4,036	3,541
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.00	0.00	0.00	0.00	13.81	9.92	2.36	1.24	1.60	5.90	9.10
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	0.31	0.33	0.28	1.18	0.00	1.23	0.77	0.83	0.52	3.34	5.85
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	3.01	0.00	0.00	54.53
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	33.19%	0.00%	0.00%	1.83%
Enterprise Value to Invested Capital (EV/IC)	1.21	1.19	1.14	1.49	1.30	1.40	1.14	1.05	1.14	1.79	3.09
Enterprise Value to Revenue (EV/Rev)	2.53	2.89	2.88	3.62	0.00	3.87	3.59	3.67	3.56	6.29	7.70
Enterprise Value to EBITDA (EV/EBITDA)	8.38	11.18	12.08	14.79	11.68	17.12	56.10	9.94	14.50	16.27	17.85
Enterprise Value to EBIT (EV/EBIT)	16.24	27.77	52.53	66.80	45.77	0.00	0.00	153.04	0.00	46.13	34.04
Enterprise Value to NOPAT (EV/NOPAT)	0.00	37.52	73.71	96.91	62.48	0.00	0.00	447.98	0.00	61.45	37.83
Enterprise Value to Operating Cash Flow (EV/OCF)	15.24	24.51	0.00	21.41	26.61	22.16	20.07	13.97	16.51	29.10	27.34
Enterprise Value to Free Cash Flow (EV/FCFF)	41.64	0.00	65.66	12.08	19.12	13.48	11.93	0.00	5.71	0.00	19.04
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	-67.13	-273.02	79.87	-666.29	39.55	22.79	8.63	4.28	9.16	5.19	2.85
Long-Term Debt to Equity	-58.83	-267.54	78.21	-666.29	39.55	21.71	8.55	4.25	9.16	5.02	2.82
Financial Leverage	-103.57	233.87	180.25	74.68	25.71	11.70	5.51	5.62	6.21	4.00	3.00
Leverage Ratio	-133.35	297.96	242.87	105.78	37.37	16.79	7.99	8.81	9.96	6.58	5.10
Compound Leverage Factor	-14.86	-127.55	-70.25	-237.02	-387.01	158.21	14.06	-73.35	39.95	-0.72	2.90
Debt to Total Capital	101.51%	100.37%	98.76%	100.15%	97.53%	95.80%	89.62%	81.06%	90.16%	83.84%	74.00%
Short-Term Debt to Total Capital	12.56%	2.02%	2.05%	0.00%	0.00%	4.57%	0.84%	0.67%	0.00%	2.73%	0.69%
Long-Term Debt to Total Capital	88.95%	98.35%	96.71%	100.15%	97.53%	91.23%	88.78%	80.40%	90.16%	81.11%	73.31%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	4.49%	4.21%	4.53%	0.32%	0.29%	0.27%	0.30%	0.30%	0.32%	0.32%	0.59%
Common Equity to Total Capital	-6.01%	-4.58%	-3.29%	-0.47%	2.18%	3.93%	10.08%	18.63%	9.52%	15.84%	25.42%
Debt to EBITDA	7.45	9.89	10.71	10.98	9.45	13.33	45.26	7.91	12.56	7.75	4.34
Net Debt to EBITDA	7.03	9.47	10.42	9.95	8.73	11.66	43.91	7.66	12.33	7.60	4.25
Long-Term Debt to EBITDA	6.53	9.69	10.49	10.98	9.45	12.69	44.84	7.84	12.56	7.50	4.30
Debt to NOPAT	-32.43	33.21	65.34	71.92	50.56	-182.23	-14.56	356.36	-75.33	29.27	9.20
Net Debt to NOPAT	-30.63	31.78	63.57	65.19	46.72	-159.40	-14.13	345.20	-73.96	28.71	9.01
Long-Term Debt to NOPAT	-28.42	32.54	63.98	71.92	50.56	-173.55	-14.43	353.43	-75.33	28.31	9.11
Altman Z-Score	0.05	0.05	-0.06	0.13	-0.13	0.15	-0.08	0.30	0.13	0.72	1.86
Noncontrolling Interest Sharing Ratio	-469.55%	1,062.92%	453.10%	24.87%	8.21%	3.92%	2.02%	2.18%	2.42%	2.11%	2.23%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	0.86	1.30	1.08	1.08	1.09	1.12	1.10	1.11	1.41	1.04	1.53
Quick Ratio	0.49	0.68	0.60	0.45	0.44	0.81	0.67	0.67	0.85	0.62	0.89
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	584	-208	357	2,528	1,546	2,468	2,525	-237	6,035	-15,195	3,320
Operating Cash Flow to CapEx	473.89%	480.00%	-333.95%	530.11%	367.88%	555.93%	956.05%	1,339.18%	888.09%	1,016.67%	0.00%
Free Cash Flow to Firm to Interest Expense	0.43	-0.16	0.61	1.70	0.97	1.49	1.40	-0.12	3.29	-9.60	3.02
Operating Cash Flow to Interest Expense	1.17	0.78	-1.24	0.96	0.70	0.91	0.83	1.17	1.14	1.43	2.10
Operating Cash Flow Less CapEx to Interest Expense	0.92	0.62	-1.61	0.78	0.51	0.74	0.75	1.08	1.01	1.29	3.19
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.36	0.33	0.30	0.28	0.00	0.26	0.24	0.22	0.21	0.28	0.30
Accounts Receivable Turnover	4.65	4.62	4.56	5.03	0.00	4.64	4.20	3.75	3.72	4.39	4.37
Inventory Turnover	1.77	1.94	2.27	2.29	0.00	2.30	2.37	2.42	2.25	2.36	2.46
Fixed Asset Turnover	5.52	5.30	5.08	5.33	0.00	6.10	6.08	6.43	7.03	7.59	6.44
Accounts Payable Turnover	4.05	4.13	5.09	6.44	0.00	5.14	6.06	7.40	6.89	6.09	6.01
Days Sales Outstanding (DSO)	78.46	78.94	80.09	72.53	0.00	78.59	87.00	97.21	98.17	83.20	83.45
Days Inventory Outstanding (DIO)	205.92	187.85	160.81	159.10	0.00	158.50	153.86	151.06	162.02	154.69	148.50
Days Payable Outstanding (DPO)	90.20	88.43	71.64	56.72	0.00	70.98	60.24	49.35	52.98	59.97	60.75
Cash Conversion Cycle (CCC)	194.18	178.36	169.25	174.91	0.00	166.12	180.62	198.92	207.21	177.93	171.20
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	20,093	21,344	20,462	20,501	22,714	23,787	26,397	30,591	30,283	36,714	20,450
Invested Capital Turnover	0.46	0.42	0.40	0.39	0.00	0.34	0.29	0.29	0.29	0.37	0.39
Increase / (Decrease) in Invested Capital	-1,251	882	-39	-2,213	-1,073	-2,610	-4,194	308	-6,431	16,264	-1,650
Enterprise Value (EV)	24,336	25,295	23,427	30,528	29,566	33,269	30,125	31,986	34,458	65,683	63,209
Market Capitalization	2,964	2,929	2,273	9,921	7,387	10,545	6,461	7,244	5,048	34,876	48,038
Book Value per Share	($3.48)	($2.80)	($1.91)	($0.30)	$1.51	$3.02	$7.81	$16.78	$9.07	$17.23	$15.73
Tangible Book Value per Share	($48.71)	($51.10)	($49.85)	($54.30)	($59.00)	($63.17)	($64.07)	($71.59)	($90.68)	($104.13)	($45.76)
Total Capital	21,294	22,306	21,026	22,620	24,530	27,031	27,120	31,388	33,104	37,314	20,772
Total Debt	21,616	22,388	20,766	22,654	23,925	25,895	24,305	25,444	29,846	31,285	15,371
Total Long-Term Debt	18,942	21,938	20,334	22,654	23,925	24,661	24,077	25,235	29,845	30,265	15,228
Net Debt	20,415	21,426	20,202	20,535	22,109	22,651	23,582	24,647	29,304	30,688	15,048
Capital Expenditures (CapEx)	337	215	218	269	302	270	157	171	235	222	-1,200
Debt-free, Cash-free Net Working Capital (DFCFNWC)	495	782	174	-1,710	-1,387	-1,289	-120	-110	927	617	1,243
Debt-free Net Working Capital (DFNWC)	1,696	1,744	738	409	429	1,955	603	687	1,469	1,214	1,566
Net Working Capital (NWC)	-978	1,294	306	409	429	721	375	478	1,468	194	1,423
Net Nonoperating Expense (NNE)	-595	1,285	530	1,252	1,032	1,641	2,475	-2,333	2,012	1,357	791
Net Nonoperating Obligations (NNO)	20,415	21,426	20,202	20,535	22,109	22,651	23,582	24,647	27,025	30,685	15,048
Total Depreciation and Amortization (D&A)	1,404	1,352	1,493	1,607	1,886	2,138	2,898	3,009	2,984	2,612	1,684
Debt-free, Cash-free Net Working Capital to Revenue	5.14%	8.93%	2.14%	-20.28%	0.00%	-14.99%	-1.43%	-1.26%	9.58%	5.91%	15.15%
Debt-free Net Working Capital to Revenue	17.62%	19.92%	9.08%	4.85%	0.00%	22.73%	7.20%	7.87%	15.19%	11.62%	19.08%
Net Working Capital to Revenue	-10.16%	14.78%	3.77%	4.85%	0.00%	8.38%	4.47%	5.48%	15.17%	1.86%	17.34%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.13)	($1.62)	($0.62)	($2.64)	($1.58)	($5.08)	($11.81)	$6.86	($6.94)	($0.85)	$2.72
Adjusted Weighted Average Basic Shares Outstanding	368M	364.90M	362M	358.90M	355.62M	352.10M	351.30M	350.20M	347.30M	342.70M	335.40M
Adjusted Diluted Earnings per Share	($0.13)	($1.62)	($0.62)	($2.64)	($1.58)	($5.08)	($11.81)	$6.83	($6.94)	($0.85)	$2.67
Adjusted Weighted Average Diluted Shares Outstanding	368M	364.90M	362M	358.90M	355.62M	352.10M	351.30M	351.80M	347.30M	342.70M	341.50M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	($1.58)	($5.08)	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	367.93M	365.41M	362.04M	359.65M	355M	352.70M	350.99M	348.84M	347.84M	343.50M	336.20M
Normalized Net Operating Profit after Tax (NOPAT)	1,125	1,100	949	842	553	-68	370	826	746	1,535	2,111
Normalized NOPAT Margin	11.69%	12.57%	11.68%	9.98%	0.00%	-0.79%	4.41%	9.47%	7.71%	14.69%	25.72%
Pre Tax Income Margin	1.74%	-4.45%	-1.59%	-12.14%	0.00%	-21.36%	-49.57%	-19.96%	-25.17%	-1.48%	12.84%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	1.10	0.69	0.76	0.31	0.41	-0.12	-1.31	0.11	-0.33	0.90	1.69
NOPAT to Interest Expense	-0.49	0.51	0.54	0.21	0.30	-0.09	-0.93	0.04	-0.22	0.68	1.52
EBIT Less CapEx to Interest Expense	0.85	0.52	0.39	0.13	0.22	-0.28	-1.40	0.02	-0.46	0.76	2.78
NOPAT Less CapEx to Interest Expense	-0.74	0.35	0.17	0.03	0.11	-0.25	-1.01	-0.05	-0.34	0.54	2.61
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-3.13%	0.91%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-28.13%	0.91%

This table displays calculated financial ratios and metrics derived from Bausch Health Companies' official financial filings.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	4.92%	6.27%	12.15%	10.89%	10.75%	9.80%	9.38%	10.17%	1.36%	-0.14%	-3.08%
EBITDA Growth	-0.97%	23.11%	100.60%	1.67%	25.25%	471.20%	-44.74%	27.76%	-23.14%	-83.09%	-37.70%
EBIT Growth	2.26%	54.31%	4,442.86%	-3.32%	61.21%	240.32%	-97.21%	136.97%	-40.65%	-168.32%	-56.50%
NOPAT Growth	-1.78%	3.25%	2,171.43%	-105.76%	60.57%	253.39%	-95.62%	24.94%	-38.60%	-113.13%	-55.87%
Net Income Growth	-11.69%	308.51%	75.92%	-103.70%	63.16%	88.54%	-194.79%	119.42%	-216.67%	-669.44%	110.99%
EPS Growth	5.88%	318.18%	77.67%	-57.14%	69.09%	90.27%	-193.64%	117.50%	-189.47%	-638.10%	111.54%
Operating Cash Flow Growth	0.00%	54.10%	43.62%	84.47%	37.01%	-17.89%	122.33%	67.48%	344.44%	1,879.17%	-323.94%
Free Cash Flow Firm Growth	279.83%	340.64%	444.06%	-144.38%	-261.25%	-398.10%	58.19%	506.37%	-68.78%	-103.64%	-119.01%
Invested Capital Growth	-4.88%	-5.86%	-3.04%	2.84%	4.33%	4.31%	1.25%	-5.48%	-1.46%	-0.19%	4.09%
Revenue Q/Q Growth	-11.72%	1.95%	4.45%	11.61%	-10.59%	7.60%	3.28%	11.47%	-11.35%	7.18%	4.02%
EBITDA Q/Q Growth	-30.15%	30.42%	-7.67%	17.74%	-13.17%	112.50%	-53.20%	45.05%	296.00%	-79.44%	8.19%
EBIT Q/Q Growth	-49.35%	68.87%	-15.87%	42.11%	-23.56%	4,871.43%	-98.21%	136.97%	166.53%	-198.80%	52.12%
NOPAT Q/Q Growth	-26.16%	17.54%	2,846.74%	-104.12%	-22.38%	2,485.71%	-93.04%	14.95%	174.15%	-173.75%	98.75%
Net Income Q/Q Growth	-187.76%	206.52%	-9,100.00%	98.70%	-63.83%	87.70%	-1,514.81%	112.92%	49.02%	-201.74%	389.93%
EPS Q/Q Growth	-166.67%	204.35%	-866.67%	117.65%	-54.55%	89.32%	-1,571.43%	112.73%	51.33%	-202.73%	375.00%
Operating Cash Flow Q/Q Growth	-64.89%	48.40%	6.58%	80.09%	-45.90%	38.30%	36.89%	33.77%	-67.58%	137.61%	-1,126.83%
Free Cash Flow Firm Q/Q Growth	-19.00%	72.95%	249.99%	14.41%	-8.38%	-147.29%	-119.35%	210.96%	434.79%	79.24%	-88.06%
Invested Capital Q/Q Growth	0.10%	-3.23%	-0.23%	-1.58%	-0.93%	-0.33%	5.83%	-0.16%	-0.95%	-3.26%	-1.20%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	68.97%	71.59%	72.27%	70.08%	70.27%	70.72%	72.16%	70.05%	70.06%	70.27%	71.46%
EBITDA Margin	27.18%	34.35%	26.85%	30.38%	28.80%	29.65%	15.01%	33.13%	25.46%	5.70%	29.72%
Operating Margin	12.22%	21.81%	12.67%	16.19%	13.05%	15.03%	0.63%	19.01%	9.00%	-10.76%	11.93%
EBIT Margin	12.04%	20.98%	12.67%	15.73%	12.35%	14.45%	0.31%	18.04%	8.49%	-11.31%	12.27%
Profit (Net Income) Margin	-3.81%	3.83%	-3.67%	-0.04%	-3.58%	-1.95%	-17.07%	1.25%	-10.75%	-18.70%	19.70%
Tax Burden Percent	182.98%	46.89%	438.10%	-2.08%	111.59%	671.43%	117.18%	34.18%	153.68%	114.85%	91.80%
Interest Burden Percent	-17.28%	38.92%	-6.60%	12.70%	-25.94%	-2.01%	-4,657.14%	20.20%	-82.42%	143.95%	174.90%
Effective Tax Rate	0.00%	53.11%	0.00%	102.08%	0.00%	0.00%	0.00%	65.82%	0.00%	0.00%	8.20%
Return on Invested Capital (ROIC)	4.03%	4.75%	3.98%	-0.15%	3.96%	4.41%	0.18%	2.61%	2.52%	-2.99%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	2.69%	3.97%	2.51%	-0.12%	2.64%	2.97%	-1.67%	2.05%	0.89%	-4.19%	0.00%
Return on Net Nonoperating Assets (RNNOA)	-271.20%	-410.92%	-224.36%	-108.62%	-3,765.62%	693.48%	-358.15%	161.05%	9,100.85%	-755.23%	0.00%
Return on Equity (ROE)	-267.17%	-406.17%	-220.38%	-108.77%	-3,761.67%	697.89%	-357.98%	163.65%	9,103.37%	-758.22%	181.21%
Cash Return on Invested Capital (CROIC)	1.80%	2.82%	7.57%	0.77%	-0.63%	-0.99%	-0.04%	-15.97%	2.65%	1.74%	-0.44%
Operating Return on Assets (OROA)	4.39%	7.50%	4.48%	5.57%	4.23%	4.77%	0.10%	5.61%	2.54%	-3.35%	0.00%
Return on Assets (ROA)	-1.39%	1.37%	-1.30%	-0.01%	-1.22%	-0.64%	-5.46%	0.39%	-3.21%	-5.53%	0.00%
Return on Common Equity (ROCE)	-1,482.98%	-2,313.37%	-1,087.57%	4,543.69%	-248,399.75%	-6,720.13%	3,082.56%	-423.50%	-2,312,255.81%	2,677.25%	-443.29%
Return on Equity Simple (ROE_SIMPLE)	6.85%	0.00%	18.48%	43.15%	42.96%	0.00%	82.54%	28.51%	44.38%	0.00%	-51.43%
Net Operating Profit after Tax (NOPAT)	193	262	223	-8.10	197	253	9.80	141	123	-165	224
NOPAT Margin	8.55%	10.22%	8.87%	-0.34%	9.14%	10.52%	0.44%	6.50%	6.30%	-7.53%	10.95%
Net Nonoperating Expense Percent (NNEP)	1.34%	0.78%	1.48%	-0.03%	1.32%	1.44%	1.85%	0.55%	1.62%	1.20%	-0.87%
Return On Investment Capital (ROIC_SIMPLE)	0.91%	1.23%	-	-	-	1.14%	-	-	-	-0.79%	-
Cost of Revenue to Revenue	31.03%	28.41%	27.73%	29.92%	29.73%	29.28%	27.84%	29.95%	29.94%	29.73%	28.54%
SG&A Expenses to Revenue	38.38%	32.04%	33.86%	34.62%	36.88%	31.81%	31.95%	32.81%	37.29%	30.37%	32.31%
R&D to Revenue	6.33%	6.37%	5.82%	6.49%	7.01%	6.31%	6.84%	7.20%	7.36%	6.48%	6.50%
Operating Expenses to Revenue	56.75%	49.79%	59.60%	53.89%	57.22%	55.69%	71.54%	51.04%	61.06%	81.03%	59.53%
Earnings before Interest and Taxes (EBIT)	272	537	318	378	266	348	7.00	391	165	-248	251
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	614	879	674	730	620	714	336	718	495	125	608
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	0.24	0.31	0.32	0.28	0.43	0.33	0.35	0.35	0.36	0.28	0.00
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	1.18	1.21	1.19	1.18	1.24	1.19	1.19	1.18	1.18	1.14	1.14
Enterprise Value to Revenue (EV/Rev)	2.43	2.53	2.61	2.67	2.91	2.89	3.00	2.85	2.94	2.88	0.00
Enterprise Value to EBITDA (EV/EBITDA)	8.17	8.38	9.02	10.23	10.94	11.18	15.29	12.23	13.41	12.08	9.47
Enterprise Value to EBIT (EV/EBIT)	15.73	16.24	18.84	24.57	25.82	27.77	81.24	42.59	72.07	52.53	22.87
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	26.12	33.52	34.93	37.52	100.16	0.00	99.67	73.71	32.66
Enterprise Value to Operating Cash Flow (EV/OCF)	14.83	15.24	17.81	19.43	24.00	24.51	22.91	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	63.72	41.64	15.46	156.12	0.00	0.00	0.00	0.00	44.38	65.66	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	-89.63	-67.13	-88.87	-95.42	-126.86	-273.02	-95.45	75.84	142.43	79.87	49.00
Long-Term Debt to Equity	-88.45	-58.83	-87.00	-93.43	-123.77	-267.54	-93.17	74.20	139.36	78.21	48.05
Financial Leverage	-100.66	-103.57	-89.42	931.84	-1,429.00	233.87	213.98	78.47	10,207.50	180.25	138.16
Leverage Ratio	-128.83	-133.35	-112.38	1,181.77	-1,805.45	297.96	269.51	102.43	13,633.75	242.87	186.41
Compound Leverage Factor	22.26	-51.90	7.42	150.07	468.33	-5.99	-12,551.24	20.70	-11,237.52	349.61	326.03
Debt to Total Capital	101.13%	101.51%	101.14%	101.06%	100.79%	100.37%	101.06%	98.70%	99.30%	98.76%	98.00%
Short-Term Debt to Total Capital	1.33%	12.56%	2.13%	2.11%	2.46%	2.02%	2.42%	2.13%	2.14%	2.05%	1.90%
Long-Term Debt to Total Capital	99.80%	88.95%	99.01%	98.95%	98.34%	98.35%	98.64%	96.57%	97.16%	96.71%	96.10%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	4.43%	4.49%	4.38%	4.42%	4.30%	4.21%	4.26%	4.49%	4.54%	4.53%	4.43%
Common Equity to Total Capital	-5.56%	-6.01%	-5.52%	-5.48%	-5.09%	-4.58%	-5.32%	-3.18%	-3.85%	-3.29%	-2.43%
Debt to EBITDA	7.42	7.45	7.86	9.03	9.24	9.89	13.40	10.56	11.54	10.71	8.31
Net Debt to EBITDA	7.03	7.03	7.58	8.77	8.93	9.47	12.93	10.26	11.24	10.42	8.12
Long-Term Debt to EBITDA	7.33	6.53	7.69	8.84	9.02	9.69	13.08	10.33	11.29	10.49	8.15
Debt to NOPAT	-32.57	-32.43	22.76	29.58	29.50	33.21	87.79	-4.57	85.77	65.34	28.67
Net Debt to NOPAT	-30.82	-30.63	21.97	28.73	28.49	31.78	84.74	-4.44	83.56	63.57	28.00
Long-Term Debt to NOPAT	-32.14	-28.42	22.28	28.96	28.78	32.54	85.69	-4.47	83.92	63.98	28.12
Altman Z-Score	0.00	-0.07	-0.02	-0.03	-0.02	-0.02	-0.09	-0.04	-0.09	-0.15	-0.38
Noncontrolling Interest Sharing Ratio	-455.07%	-469.55%	-393.50%	4,277.27%	-6,503.45%	1,062.92%	961.11%	358.78%	25,500.00%	453.10%	344.63%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	1.35	0.86	1.19	1.19	1.23	1.30	1.20	1.12	1.08	1.08	1.05
Quick Ratio	0.75	0.49	0.62	0.62	0.63	0.68	0.64	0.59	0.56	0.60	0.58
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	1,225	1,513	875	-583	-681	-629	-254	1,314	423	-126	-608
Operating Cash Flow to CapEx	183.48%	566.98%	570.42%	487.18%	257.32%	397.96%	671.43%	735.71%	327.66%	719.70%	-2,338.89%
Free Cash Flow to Firm to Interest Expense	3.71	4.49	2.53	-1.73	-1.98	-1.74	-0.75	4.12	1.38	-1.10	0.00
Operating Cash Flow to Interest Expense	0.64	1.78	1.17	1.12	0.61	1.08	0.83	0.65	0.50	4.13	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.29	1.47	0.97	0.89	0.38	0.81	0.71	0.56	0.35	3.56	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.36	0.36	0.35	0.35	0.34	0.33	0.32	0.31	0.30	0.30	0.00
Accounts Receivable Turnover	4.72	4.65	4.69	4.79	4.80	4.62	4.63	4.93	5.01	4.56	0.00
Inventory Turnover	1.75	1.77	1.89	1.88	1.83	1.94	2.15	2.13	2.11	2.27	0.00
Fixed Asset Turnover	5.41	5.52	5.62	5.52	5.42	5.30	5.53	5.31	5.13	5.08	0.00
Accounts Payable Turnover	4.51	4.05	4.47	4.91	4.35	4.13	4.75	4.69	4.64	5.09	0.00
Days Sales Outstanding (DSO)	77.27	78.46	77.86	76.26	76.05	78.94	78.77	74.05	72.87	80.09	0.00
Days Inventory Outstanding (DIO)	208.56	205.92	193.54	193.71	199.31	187.85	169.54	171.11	172.75	160.81	0.00
Days Payable Outstanding (DPO)	81.01	90.20	81.73	74.30	83.89	88.43	76.83	77.75	78.64	71.64	0.00
Cash Conversion Cycle (CCC)	204.82	194.18	189.68	195.66	191.46	178.36	171.48	167.41	166.97	169.25	0.00
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	20,113	20,093	20,763	20,810	21,145	21,344	21,415	20,235	20,267	20,462	21,151
Invested Capital Turnover	0.47	0.46	0.45	0.45	0.43	0.42	0.40	0.40	0.40	0.40	0.00
Increase / (Decrease) in Invested Capital	-1,032	-1,251	-652	575	878	882	264	-1,173	-300	-39	832
Enterprise Value (EV)	23,677	24,336	24,685	24,542	26,135	25,295	25,590	23,808	24,000	23,427	24,168
Market Capitalization	2,381	2,964	2,996	2,557	3,875	2,929	2,995	2,910	2,933	2,273	2,492
Book Value per Share	($3.22)	($3.48)	($3.20)	($3.20)	($3.04)	($2.80)	($3.24)	($1.82)	($2.21)	($1.91)	($1.45)
Tangible Book Value per Share	($47.92)	($48.71)	($49.02)	($49.63)	($50.32)	($51.10)	($52.41)	($48.36)	($49.53)	($49.85)	($51.29)
Total Capital	21,270	21,294	21,265	21,433	21,900	22,306	22,195	20,823	20,798	21,026	21,648
Total Debt	21,510	21,616	21,507	21,660	22,074	22,388	22,430	20,552	20,653	20,766	21,215
Total Long-Term Debt	21,228	18,942	21,054	21,208	21,536	21,938	21,894	20,108	20,207	20,334	20,804
Net Debt	20,353	20,415	20,757	21,037	21,319	21,426	21,650	19,964	20,122	20,202	20,718
Capital Expenditures (CapEx)	115	106	71	78	82	98	42	28	47	66	54
Debt-free, Cash-free Net Working Capital (DFCFNWC)	601	495	548	671	774	782	580	350	229	174	93
Debt-free Net Working Capital (DFNWC)	1,758	1,696	1,298	1,294	1,529	1,744	1,360	938	760	738	590
Net Working Capital (NWC)	1,476	-978	845	842	991	1,294	824	494	314	306	179
Net Nonoperating Expense (NNE)	279	164	315	-7.10	274	300	392	114	332	245	-179
Net Nonoperating Obligations (NNO)	20,353	20,415	21,005	21,037	21,319	21,426	21,650	19,964	20,122	20,202	20,718
Total Depreciation and Amortization (D&A)	342	342	356	352	354	366	329	327	330	373	357
Debt-free, Cash-free Net Working Capital to Revenue	6.18%	5.14%	5.78%	7.29%	8.63%	8.93%	6.79%	4.19%	2.81%	2.14%	0.00%
Debt-free Net Working Capital to Revenue	18.07%	17.62%	13.70%	14.06%	17.05%	19.92%	15.92%	11.23%	9.33%	9.08%	0.00%
Net Working Capital to Revenue	15.17%	-10.16%	8.92%	9.15%	11.05%	14.78%	9.65%	5.92%	3.85%	3.77%	0.00%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.16)	$0.24	($0.23)	$0.03	($0.17)	($0.11)	($1.03)	$0.07	($0.55)	($1.13)	$1.10
Adjusted Weighted Average Basic Shares Outstanding	369.60M	368M	368.40M	367.90M	366.80M	364.90M	365.40M	364.80M	363.30M	362M	362.50M
Adjusted Diluted Earnings per Share	($0.16)	$0.24	($0.23)	$0.03	($0.17)	($0.11)	($1.03)	$0.07	($0.55)	($1.13)	$1.10
Adjusted Weighted Average Diluted Shares Outstanding	369.60M	368M	368.40M	370.20M	366.80M	364.90M	365.40M	367.10M	363.30M	362M	363.40M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	369.55M	367.93M	367.80M	367.10M	366.80M	365.41M	365.20M	364.33M	363.72M	362.04M	361.87M
Normalized Net Operating Profit after Tax (NOPAT)	194	412	223	284	206	333	304	326	139	274	343
Normalized NOPAT Margin	8.58%	16.08%	8.90%	11.83%	9.56%	13.81%	13.57%	15.02%	7.13%	12.48%	16.78%
Pre Tax Income Margin	-2.08%	8.17%	-0.84%	2.00%	-3.20%	-0.29%	-14.57%	3.65%	-7.00%	-16.28%	21.46%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.82	1.59	0.92	1.12	0.77	0.96	0.02	1.23	0.54	-2.16	0.00
NOPAT to Interest Expense	0.59	0.78	0.64	-0.02	0.57	0.70	0.03	0.44	0.40	-1.44	0.00
EBIT Less CapEx to Interest Expense	0.48	1.28	0.71	0.89	0.53	0.69	-0.10	1.14	0.38	-2.73	0.00
NOPAT Less CapEx to Interest Expense	0.24	0.46	0.44	-0.25	0.33	0.43	-0.10	0.35	0.25	-2.01	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions About Bausch Health Companies' Financials

When does Bausch Health Companies's fiscal year end?

According to the most recent income statement we have on file, Bausch Health Companies' financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Bausch Health Companies' net income changed over the last 10 years?

Bausch Health Companies' net income appears to be on an upward trend, with a most recent value of -$72 million in 2024, falling from $880 million in 2014. The previous period was -$611 million in 2023. See Bausch Health Companies' forecast for analyst expectations on what’s next for the company.

What is Bausch Health Companies's operating income?

Bausch Health Companies's total operating income in 2024 was $1.55 billion, based on the following breakdown:

Total Gross Profit: $6.84 billion
Total Operating Expenses: $5.30 billion

How has Bausch Health Companies revenue changed over the last 10 years?

Over the last 10 years, Bausch Health Companies' total revenue changed from $8.21 billion in 2014 to $9.63 billion in 2024, a change of 17.3%.

How much debt does Bausch Health Companies have?

Bausch Health Companies' total liabilities were at $26.85 billion at the end of 2024, a 2.1% decrease from 2023, and a 28.4% increase since 2014.

How much cash does Bausch Health Companies have?

In the past 10 years, Bausch Health Companies' cash and equivalents has ranged from $322.60 million in 2014 to $3.24 billion in 2019, and is currently $1.18 billion as of their latest financial filing in 2024.

How has Bausch Health Companies' book value per share changed over the last 10 years?

Over the last 10 years, Bausch Health Companies' book value per share changed from 15.73 in 2014 to -3.48 in 2024, a change of -122.1%.

Related Companies

This page (NYSE:BHC) was last updated on 5/31/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Bausch Health Companies (BHC) Financials

Frequently Asked Questions About Bausch Health Companies' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Bausch Health Companies (BHC) Financials

Annual Income Statements for Bausch Health Companies

Quarterly Income Statements for Bausch Health Companies

Annual Cash Flow Statements for Bausch Health Companies

Quarterly Cash Flow Statements for Bausch Health Companies

Annual Balance Sheets for Bausch Health Companies

Quarterly Balance Sheets for Bausch Health Companies

Annual Metrics And Ratios for Bausch Health Companies

Quarterly Metrics And Ratios for Bausch Health Companies

Frequently Asked Questions About Bausch Health Companies' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools